UBRELVY
LIVE

Serial Number

88185227

Owner

Allergan Pharmaceuticals International Limited

Attorney

Matthew O. Brady

First Use Date

Jan 22, 2020

Filing Date

Nov 7, 2018

Add to watchlist:

No watchlists yet
View on USPTO

UBRELVY Trademark

Serial Number: 88185227 • Registration: 6075800

UBRELVY is a trademark filed by Allergan Pharmaceuticals International Limited on November 7, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Allergan Pharmaceuticals International Limited (5 trademarks)

Clonshaugh Business & Technology Park
DUBLIN 17 D17E400 , IE

Entity Type: 77

Trademark Details

Filing Date

November 7, 2018

Registration Date

June 9, 2020

First Use Anywhere

January 22, 2020

First Use in Commerce

January 22, 2020

Published for Opposition

March 5, 2019

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

TEAS SECTION 8 & 15 RECEIVED
Jun 9, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 9, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 2, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 1, 2020 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 20, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 20, 2020 AITU
USE AMENDMENT FILED
Apr 6, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 6, 2020 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 30, 2019 EXRA
SOU EXTENSION 1 GRANTED
Oct 28, 2019 EX1G
SOU EXTENSION 1 FILED
Oct 28, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 28, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 30, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Mar 5, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 13, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2019 CNSA
ASSIGNED TO EXAMINER
Jan 24, 2019 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 27, 2018 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 24, 2018 NWOS
NEW APPLICATION ENTERED
Nov 10, 2018 NWAP